ENTITY
3SBio

3SBio (1530 HK)

196
Analysis
Health Care • China
3SBio is a leading biotechnology company engaged in the research, development, manufacturing, and marketing of biopharmaceutical products. The company's diverse portfolio addresses therapeutic areas such as nephrology, oncology, supportive cancer care, inflammation, infectious diseases, autoimmune diseases, metabolism, and dermatology, with key products including EPIAO and TPIAO. 3SBio was founded in 1993 and is headquartered in Shenyang, China.
more
•28 Jan 2021 17:22

HK Shorts: Squeeze-O-Meter

Following the GameStop saga, we try to identify stocks in HK that could be susceptible to a short squeeze based on short interest vs issued shares...

Logo
1.4k Views
Share
•14 Jan 2021 19:04

Innovent Biologics Placement - Momentum Is Very Strong but past Deals Have Been Mixed

Innovent Biologics Inc (1801 HK) is looking to raise about U$600m to fund its clinical trials  and product licensing and possible M&A. This will be...

Logo
586 Views
Share
•05 Jan 2021 09:51

Pre-IPO Bio-Thera Solutions - Insights on Pipeline and the Competitive Landscape

This article summarized the insights on major products of Bio-Thera Solutions in the pipeline and related competitive landscape with other key...

Logo
548 Views
Share
bullish•Alibaba Health
•18 Dec 2020 20:56

China Healthcare: Macro Themes

This Insight summarizes the takeaways from a recent China healthcare industry conference.  There is much talk of pressures on the industry, but...

Share
•02 Dec 2020 09:36

Harbour Biomed IPO: Positive Thoughts in Brief

This Insight includes a brief analysis of Harbour Biomed and its proposed listing on the HKEX. We like the deal at the price range offered.

Share
x